AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05797233
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3
Trial: NCT04532502
Drug: Anesthetics, Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work environmental exposure
Trial: NCT05433584
Drug: Antihyperglycemic medication
RxNorm normalized name: ANTIHYPOGLYCEMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT04828161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV on day 1 only.
Trial: NCT06065657
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
Trial: NCT05583721
Drug: [13N]NH3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.
Trial: NCT05950802
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Higher dose than traditional conditioning chemo
Trial: NCT05814159
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sub cutaneous daily injection
Trial: NCT04956666
Drug: Lyophilized S95014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient was administrated, over 1 to 2 hours, every 2 weeks Lyophilized S95014 intravenously at the dose of 1000, 2000 or 2500U/m2, as per investigator's judgement.~In total, 9 infusions of lyophilized S95014 were administrated (at week 7, 9, 11, 15, 17, 19, 23, 25 and 27).Patients received other backbone chemotherapy agents as per ALL-MB 2015.
Trial: NCT05382338
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06130826
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive M5A-IL2 ICK SC
Trial: NCT05983588
Drug: RAVICTI 1.1 g/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)
Trial: NCT05983588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)
Trial: NCT05342792
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
Trial: NCT06557772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Injection solution Route of administration: SC injection
Trial: NCT05020860
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 IV administered on Day 1 of each 14-day cycle
Trial: NCT05020860
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 IV administered on Day 1 of each 14-day cycle
Trial: NCT06362746
Drug: Non-immunogenic recombinant staphylokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
Trial: NCT06362746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of placebo reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
Trial: NCT05764876
Drug: Azithromycin Oral Tablet
RxNorm normalized name: azithromycin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet of azithromycin 30mg/kg maximum 2gr single dose.
Trial: NCT04942626
Drug: Kineret 100 MG in 0.67 ML Prefilled Syringe
RxNorm normalized name: Kineret 100 MG in 0.67 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 100 mg s.c. (Kineret) will be administered from day -10 (i.e. 10 days before initiation of RT) to the last day of RT.
Trial: NCT04942626
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered using a 3+3 dose escalation design (500 mg/m2 bid, 650 mg/m2 bid and 825 mg/m2 bid po, respectively) from day 1 to day 40 of RT including weekends.
Trial: NCT05268120
Drug: doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both first choice treatments in Dutch guideline for MRSA decolonization
Trial: NCT05464810
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05753215
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to randomization, SOC antibacterial therapy will be selected by the subject's treating physician.
Trial: NCT04782830
Drug: placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill will be taken for 7 days at the same frequency as their regular treatment with either midodrine or atomoxetine.
Trial: NCT06288477
Drug: Neo-Putty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).
Trial: NCT05739383
Drug: Placebo in 1.5ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo in 1.5ml solution for injection
Trial: NCT06095258
Drug: Traditional Chinese medicine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: About four to six Chinese medicine practitioners with five to twenty years of clinical work experience will be responsible for patient diagnosis and prescription treatment, and use a uniformly designed data collection form to record the patient's medical history, clinical symptoms and signs, tongue and pulse conditions, and other information. Patients in the treatment group will receive individualized Chinese medicine treatment prescriptions. Patients in the control group received conventional Western medicine treatment, and about 3 to four Western medicine practitioners with five to twenty years of work experience will be responsible for the conventional medicine prescription. The treatment of the two groups will last for four weeks, and the patients will be followed up for four weeks after the treatment. A patient diary will be provided to all participants for recording the drug compliance and any adverse event during the treatment period.
Trial: NCT05655312
Drug: [203Pb]VMT01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[203Pb\]VMT01 is administered intravenous (IV) as an imaging agent for SPECT/CT
Trial: NCT04799327
Drug: SHR20004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR20004：low dose
Trial: NCT04799327
Drug: SHR20004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR20004: medium dose
Trial: NCT04799327
Drug: SHR20004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR20004: high dose
Trial: NCT04799327
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05655312
Drug: [212Pb]VMT01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with positive uptake of \[203Pb\]VMT01 will receive a fixed dose of \[212Pb\]VMT01 administered IV every 8 weeks starting at Cycle 1 Day 1.
Trial: NCT06095258
Drug: Western medicine treatment
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine doctors will mainly use symptomatic drugs to treat long COVID. For example, cough medicine (such as codeine), bronchodilators (such as ventolin), expectorants (such as fluimucil) and so on are used to treat cough, shortness of breath, or other respiratory symptoms. Non-steroidal anti-inflammatory painkillers (such as panadol) are often used for treating headaches, and sedative-hypnotic drugs (such as stilnox) are often used to treat insomnia.
Trial: NCT05170464
Drug: Caffeine Powder
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive powdered caffeine dissolved in one cup of water (1.2mg/kg)
Trial: NCT05488171
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of placebo.
Trial: NCT06013423
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Receive IV
Trial: NCT00429923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05769309
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl boluses of 0.5-to-1 µg/kg titrated according to haemodynamic parameters.
Trial: NCT06068023
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients meeting the criteria of post-operative adenocarcinoma of the ampulla of Vater will be enrolled, with adjuvant chemotherapy commencing within 8 weeks of recovery from surgery. Those undergoing palliative intent surgery or palliative chemotherapy are ineligible for the ADAPTA study.~The ADAPTA study's adjuvant chemotherapy involves 8-12 FOLFIRINOX cycles (Arm 2) repeated 2 weeks. Given patient outcomes, 8 cycles of FOLFIRINOX are deemed sufficient due to completion challenges in prior research. FOLFIRINOX regimen mirrors the modified version from the ACCORD/PRODIGE trial for metastatic pancreatic cancer. This trial adapts mFOLFIRINOX for standard practice.
Trial: NCT06068023
Drug: Capox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: or 8 CAPOX cycles (Arm 1) every 3 weeks.
Trial: NCT05053893
Drug: EPO; ACEI / ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Select the appropriate ACEI /ARB according to the subject's situation or follow its previous medication
Trial: NCT04986423
Drug: ZEN003694
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72 mg PO QD
Trial: NCT05681299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be taken by nightly subcutaneous injection at 9-11 pm.
Trial: NCT05081765
Drug: Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: correlation between C through and taken drug
Trial: NCT06273462
Drug: Palmitoylethanolamide 600mg twice a day
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg palmitoylethanolamide twice a day
Trial: NCT05600660
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.
Trial: NCT06557018
Drug: traditional peri-articular injection
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: traditional peri-articular injection group
Trial: NCT06382831
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Control given Opioid balanced anesthesia
Trial: NCT05089279
Drug: D113
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT05882045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04895748
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mTOR inhibitor
Trial: NCT06301802
Drug: Anticholinergic
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antimuscarinic once daily
Trial: NCT05664880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsule to 2 MCG Paricalcitol Oral Capsule
Trial: NCT06079398
Drug: Navepegritide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly subcutaneous injection of 100 µg/kg Navepegritide
Trial: NCT06079398
Drug: Placebo for Navepegritide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide
Trial: NCT05855746
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant receive, in addition to standard of care therapy, six months of placebo (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization.~The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision.
Trial: NCT05128903
Drug: [18F]DPA714
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection~* Before or within 2 weeks of starting radiation therapy~* Before starting chemotherapy~* 1 year after the start of radiation therapy Timing cont.~* 1.5 to 2 years after the start of radiation therapy
Trial: NCT06166472
Drug: AK132
RxNorm normalized name: Aklomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion, specified dose on specified days.
Trial: NCT04970446
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive a one week course of antibiotic therapy.
Trial: NCT04892940
Drug: Analgesic protocol
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized in the control group receive the usual analgesic protocol of the department postoperatively.
Trial: NCT05263219
Drug: dTACE-HAIC protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
Trial: NCT05263219
Drug: HAIC protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; and 5-FU, 400 mg/m2 bolus infusion and then 2400 mg/m2 continuous infusion over 46 h.
Trial: NCT05368142
Drug: Nocardia rubra Cell Wall Skeleton
RxNorm normalized name: Spongia officinalis skeleton extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocardia rubra cell wall skeleton for external application
Trial: NCT03541889
Drug: FLT imaging and TK1 blood measurements
RxNorm normalized name: SUS SCROFA BLOOD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.
Trial: NCT05259033
Drug: IcoSema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IcoSema once weekly subcutaneously (s.c., under the skin) using a needle and a pen.~For about 1 year and 1 month.
Trial: NCT05050136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules matched to study drug without the active pharmaceutical ingredient
Trial: NCT06143059
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sterile, 95% ethanol will be administered through IV infusion
Trial: NCT05113290
Drug: Recombinant Human Adenovirus Type 5 injection
RxNorm normalized name: adenovirus, type 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral injection of lesions with dose of 3 vials (1.5 × 10\^12 vp) if the sum of the maximum lesion diameters was \> 10 cm, 2 vials (1.0 × 10\^12 vp) if the sum of the maximum lesion diameters was ≤ 10 cm. The cycle is 21 days up to 2-5 cycles.
Trial: NCT06031610
Drug: drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotid artery stenosis requires taking antiplatelet aggregation drugs and statin lipid-lowering drugs. It can inhibit platelet aggregation, stabilize plaque, reduce vascular inflammatory factors, and prevent further development of atherosclerosis.
Trial: NCT06466135
Drug: WAL0921
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions.
Trial: NCT06466135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo product Participants receive an intravenous infusion of placebo once every 2 weeks for 7 total infusions.
Trial: NCT05384678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Placebo (saline infusion) will be administered.
Trial: NCT05384678
Drug: N,N-Dimethyltryptamine (108 mg) + dose titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose rate of 1.2 mg/min will be administered with subsequent patient-guided dose titration
Trial: NCT05838716
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05769608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 12 weeks
Trial: NCT04586023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive teriflunomide-matching placebo or fenebrutinib-matching placebo.
Trial: NCT05960851
Drug: LY3871801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05960851
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06313047
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.
Trial: NCT06397001
Drug: nL-SAA1-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized antisense oligonucleotide
Trial: NCT05853835
Drug: LPX-TI641
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).
Trial: NCT05370521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active dosage form taken once daily.
Trial: NCT06259123
Drug: [177Lu]Lu-PSMA I&T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cycles of 5 GBq \[177Lu\]Lu-PSMA I\&T at 6-week intervals prior radical prostatectomy for patients with oligometastatic prostate cancer
Trial: NCT05485831
Drug: Epidiolex 100 mg/mL Oral Solution
RxNorm normalized name: Epidiolex 100 MG/ML Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed in routine clinical practice in Italy.
Trial: NCT05579626
Drug: high-intensity statin arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: •high-intensity statin strategy (standard arm): rosuvastatin 20 mg PO qd, once daily
Trial: NCT05382559
Drug: ASP3082
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion
Trial: NCT05382559
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Infusion
Trial: NCT05382559
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Infusion
Trial: NCT05299242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline \[0.9% NaCl\]
Trial: NCT05158608
Drug: Post-transplantation Cyclophosphamide at dose 25 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
Trial: NCT05158608
Drug: Post-transplantation Cyclophosphamide at dose 50 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
Trial: NCT06413498
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT04781140
Drug: 100mg SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg SPN-812 will be administered once daily and compared to Placebo